Table 1. FISH/CISH by histology.
| Histology* | Gene** | |||
|---|---|---|---|---|
| ISH cMET | ISH EGFR | ISH HER2 | ||
| All (n = 2539) | Total Positive | 20 | 181 | 9 |
| Total Cases | 761 | 1072 | 925 | |
| % Positive | 2.6 | 16.9 | 1.0 | |
| Angiosarcoma (n = 77) | Total Positive | 0 | 1 | 0 |
| Total Cases | 26 | 34 | 33 | |
| % Positive | 0.0 | 2.9 | 0.0 | |
| Chondrosarcoma (n = 97) | Total Positive | 1 | 2 | 1 |
| Total Cases | 32 | 24 | 42 | |
| % Positive | 3.1 | 8.3 | 2.4 | |
| Clear cell sarcoma (n = 16) | Total Positive | 0 | 1 | 0 |
| Total Cases | 4 | 8 | 4 | |
| % Positive | 0.0 | 12.5 | 0.0 | |
| DSRCT (n = 8) | Total Positive | 0 | 2 | 0 |
| Total Cases | 11 | 10 | 15 | |
| % Positive | 0.0 | 20.0 | 0.0 | |
| ESS (n = 91) | Total Positives | 0 | 4 | 1 |
| Total Cases | 33 | 50 | 31 | |
| % Positive | 0.0 | 8.0 | 3.2 | |
| Ewing's sarcoma (n = 83) | Total Positive | 0 | 2 | 0 |
| Total Cases | 23 | 30 | 27 | |
| % Positive | 0.0 | 6.7 | 0.0 | |
| Fibrosarcoma (n = 63) | Total Positive | 0 | 5 | 0 |
| Total Cases | 21 | 33 | 21 | |
| % Positive | 0.0 | 15.2 | 0.0 | |
| Giant cell tumor (n = 13) | Total Positive | 0 | 2 | 0 |
| Total Cases | 3 | 7 | 4 | |
| % Positive | 0.0 | 28.6 | 0.0 | |
| Liposarcoma (n = 220) | Total Positive | 3 | 14 | 0 |
| Total Cases | 62 | 80 | 93 | |
| % Positive | 4.8 | 17.5 | 0.0 | |
| Myxoid (n = 46) | Total Positive | 1 | 0 | 0 |
| Total Cases | 14 | 15 | 18 | |
| % Positive | 7.1 | 0.0 | 0.0 | |
| Dedifferentiated (n = 77) | Total Positive | 0 | 1 | 0 |
| Total Cases | 24 | 28 | 41 | |
| % Positive | 0.0 | 3.6 | 0.0 | |
| Well-differentiated (n = 31) | Total Positive | 0 | 5 | 0 |
| Total Cases | 11 | 12 | 13 | |
| % Positive | 0.0 | 41.7 | 0.0 | |
| Pleomorphic (n = 30) | Total Positive | 2 | 5 | 0 |
| Total Cases | 7 | 8 | 10 | |
| % Positive | 28.6 | 62.5 | 0.0 | |
| Other/Unknown (n = 36) | Total Positive | 0 | 3 | 0 |
| Total Cases | 6 | 17 | 11 | |
| % Positive | 0.0 | 17.6 | 0.0 | |
| LMS (nonuterine) (n = 350) | Total Positive | 4 | 27 | 3 |
| Total Cases | 112 | 128 | 137 | |
| % Positive | 3.6 | 21.1 | 2.2 | |
| LMS (uterine) (n = 401) | Total Positive | 4 | 43 | 1 |
| Total Cases | 96 | 220 | 106 | |
| % Positive | 4.2 | 19.5 | 0.9 | |
| MPNST (n = 36) | Total Positive | 0 | 4 | 1 |
| Total Cases | 13 | 14 | 18 | |
| % Positive | 0.0 | 28.6 | 5.6 | |
| Osteosarcoma (n = 95) | Total Positive | 1 | 9 | 0 |
| Total Cases | 18 | 46 | 24 | |
| % Positive | 5.6 | 19.6 | 0.0 | |
| PEComa (n = 17) | Total Positive | 0 | 2 | 0 |
| Total Cases | 9 | 7 | 9 | |
| % Positive | 0.0 | 28.6 | 0.0 | |
| Rhabdomyosarcoma (n = 82) | Total Positive | 0 | 4 | 1 |
| Total Cases | 27 | 26 | 36 | |
| % Positive | 0.0 | 15.4 | 2.8 | |
| Alveolar (n = 18) | Total Positive | 0 | 1 | 0 |
| Total Cases | 1 | 4 | 3 | |
| % Positive | 0.0 | 25.0 | 0.0 | |
| Embryonal (n = 19) | Total Positive | 0 | 0 | 0 |
| Total Cases | 7 | 8 | 6 | |
| % Positive | 0.0 | 0.0 | 0.0 | |
| Pleomorphic (n = 9) | Total Positive | 0 | 0 | 0 |
| Total Cases | 5 | 1 | 7 | |
| % Positive | 0.0 | 0.0 | 0.0 | |
| Other/Unknown (n = 36) | Total Positive | 0 | 3 | 1 |
| Total Cases | 14 | 12 | 20 | |
| % Positive | 0.0 | 25.0 | 5.0 | |
| SFT (n = 56) | Total Positive | 0 | 1 | 0 |
| Total Cases | 11 | 28 | 18 | |
| % Positive | 0.0 | 3.6 | 0.0 | |
| Synovial sarcoma (n = 70) | Total Positive | 1 | 0 | 0 |
| Total Cases | 19 | 31 | 21 | |
| % Positive | 5.3 | 0.0 | 0.0 | |
| UPS (n = 166) | Total Positive | 2 | 30 | 0 |
| Total Cases | 54 | 76 | 66 | |
| % Positive | 3.7 | 39.5 | 0.0 | |
| Other (n = 454) | Total Positive | 4 | 28 | 1 |
| Total Cases | 156 | 182 | 177 | |
| % Positive | 2.6 | 15.4 | 0.6 | |
DSRCT = desmoplastic small round cell tumor, ESS = endometrial stromal sarcoma, LMS = leiomyosarcoma, UPS/MFH = undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, MPNST = malignant peripheral nerve sheath tumor, PEComa = perivascular epithelioid cell tumor, SFT = solitary fibrous tumor,
*
Histologies with no amplification of genes tested: alveolar soft part sarcoma, chordoma, desmoid, epithelioid hemangioendothelioma, epithelioid sarcoma.
**
PIK3CA – 3/9 cases amplified( LMS, osteosarcoma, other); TOPO2A – 2/118 cases amplified(LMS, other); cMYC – 1/18 cases amplified(osteosarcoma); ALK – 1/65 cases amplified (LMS).